JP2002528502A - チプラナビルの薬物動態を改善する方法 - Google Patents

チプラナビルの薬物動態を改善する方法

Info

Publication number
JP2002528502A
JP2002528502A JP2000579225A JP2000579225A JP2002528502A JP 2002528502 A JP2002528502 A JP 2002528502A JP 2000579225 A JP2000579225 A JP 2000579225A JP 2000579225 A JP2000579225 A JP 2000579225A JP 2002528502 A JP2002528502 A JP 2002528502A
Authority
JP
Japan
Prior art keywords
tipranavir
ritonavir
effective amount
therapeutically effective
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000579225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002528502A5 (enExample
Inventor
ジェイムズ・ジェイ・フェリー
ジョン・アール・ボールドウィン
マリー・ティ・ボリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of JP2002528502A publication Critical patent/JP2002528502A/ja
Publication of JP2002528502A5 publication Critical patent/JP2002528502A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000579225A 1998-11-04 1999-10-29 チプラナビルの薬物動態を改善する方法 Pending JP2002528502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10696398P 1998-11-04 1998-11-04
US60/106,963 1998-11-04
PCT/US1999/021469 WO2000025784A1 (en) 1998-11-04 1999-10-29 Method for improving the pharmacokinetics of tipranavir

Publications (2)

Publication Number Publication Date
JP2002528502A true JP2002528502A (ja) 2002-09-03
JP2002528502A5 JP2002528502A5 (enExample) 2006-06-22

Family

ID=22314155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000579225A Pending JP2002528502A (ja) 1998-11-04 1999-10-29 チプラナビルの薬物動態を改善する方法

Country Status (13)

Country Link
US (1) US6147095A (enExample)
EP (1) EP1126847A1 (enExample)
JP (1) JP2002528502A (enExample)
CN (1) CN1154491C (enExample)
AU (1) AU762349B2 (enExample)
BR (1) BR9914940A (enExample)
CA (1) CA2346131C (enExample)
CO (1) CO5160321A1 (enExample)
HK (1) HK1040625B (enExample)
MY (1) MY118526A (enExample)
PE (1) PE20001296A1 (enExample)
TW (1) TW580387B (enExample)
WO (1) WO2000025784A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511538A (ja) * 2002-12-16 2006-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用
JP2014518375A (ja) * 2011-05-30 2014-07-28 ストリング セラピューティックス インコーポレイテッド ポイント・オブ・ケア薬物動態プロフィールによる治療薬モニタリングおよび用量投与のための方法および組成物

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
ES2298286T3 (es) * 2000-10-31 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Formulaciones de dosis orales auto-emulsionantes de inhibidores de proteasa de piranona.
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
EP1610781A1 (en) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of tipranavir and a further antiretroviral compound
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
EP1812069A2 (en) * 2004-11-08 2007-08-01 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and etravirine
US20060135562A1 (en) * 2004-11-16 2006-06-22 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and darunavir
EP1814549A2 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
WO2006060175A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
WO2006060177A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
JP2008521896A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びｇｗ６９５６３４を共に投与することを含むｈｉｖ感染症の治療方法
WO2008112289A2 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
MX2012011415A (es) * 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6009059951, ＣＨＯＮＧ， Ｋ．Ｔ． ｅｔ ａｌ．, ＡＮＴＩＭＩＣＲＯＢＩＡＬ ＡＧＥＮＴＳ ＡＮＤ ＣＨＥＭＯＴＨＥＲＡＰＹ, 1997, Ｖｏｌ．４１， Ｎｏ．１１, ｐ．２３６７−２３７３ *
JPN6009059952, ＢＯＲＩＮ， Ｍ．Ｔ． ｅｔ ａｌ．, ＡＢＳＴＲＡＣＳＴ ＯＦ ＴＨＥ ＩＮＴＥＲＳＣＩＥＮＣＥ ＣＯＮＦＥＲＥＮＣＥ ＯＮ ＡＮＴＩＭＩＣＲＯＢＩＡＬ ＡＧＥＮＴＳ ＡＮＤ ＣＨＥＭＯＴＨＥＲＡＰＹ, 1997, Ｖｏｌ．３７, ｐ．２７９ *
JPN6009059953, ＭＡＲＫＯＷＩＴＺ， Ｍ． ｅｔ ａｌ．, ＴＨＥ ＮＥＷ ＥＮＧＬＡＮＤ ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＥ, 1995, Ｖｏｌ．３３３， Ｎｏ．２３, ｐ．１５３４−１５３９ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511538A (ja) * 2002-12-16 2006-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用
JP2014518375A (ja) * 2011-05-30 2014-07-28 ストリング セラピューティックス インコーポレイテッド ポイント・オブ・ケア薬物動態プロフィールによる治療薬モニタリングおよび用量投与のための方法および組成物
JP2017207508A (ja) * 2011-05-30 2017-11-24 オートテリック エルエルシー ポイント・オブ・ケア薬物動態プロフィールによる治療薬モニタリングおよび用量投与のための方法および組成物

Also Published As

Publication number Publication date
CO5160321A1 (es) 2002-05-30
EP1126847A1 (en) 2001-08-29
CN1154491C (zh) 2004-06-23
CN1324237A (zh) 2001-11-28
BR9914940A (pt) 2001-07-10
PE20001296A1 (es) 2000-11-23
CA2346131A1 (en) 2000-05-11
WO2000025784A1 (en) 2000-05-11
CA2346131C (en) 2013-01-15
AU762349B2 (en) 2003-06-26
MY118526A (en) 2004-11-30
TW580387B (en) 2004-03-21
AU1440400A (en) 2000-05-22
HK1040625B (zh) 2005-04-01
US6147095A (en) 2000-11-14
HK1040625A1 (en) 2002-06-21

Similar Documents

Publication Publication Date Title
US6147095A (en) Method for improving the pharmacokinetics of tipranavir
Romero et al. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
CN103108651A (zh) Cyp3a药物代谢的抑制
HUP0103319A2 (hu) Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk
Craig et al. Antiviral synergy between inhibitors of HIV proteinase and reverse transcriptase
US6194430B1 (en) Viral treatment
US7829548B2 (en) Compounds useful in the treatment of HIV
Ghosh et al. Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease
Baba Cellular factors as alternative targets for inhibition of HIV-1
JP2004538334A (ja) Ｈｉｖ感染の治療に使用される薬剤とその成分と使用法
JP2004083576A (ja) Ｈｉｖ感受性株に対して活性をもち、ヌクレオシド系ならびに非ヌクレオシド系の逆転写酵素阻害剤、およびプロテアーゼ阻害剤に対し抵抗性のｈｉｖ株に対して活性をもつ抗レトロウイルス治療薬を得るための、クロロキン、ヒドロキシクロロキン、および４アミノ−キノリン酸誘導体の使用
US6225307B1 (en) Viral treatment
EP1712231A2 (en) Method for improving the pharmacokinetics of tipranavir
WO2019003251A1 (en) PHARMACEUTICAL COMPOSITIONS
JP2023528196A (ja) ウイルス感染症を予防又は治療するための化合物
Stanic et al. Review of antiretroviral agents for the treatment of HIV infection.
Redshaw et al. Human Immunodeficiency Virus Protease Inhibitors
Koren et al. Scientific basis of antiretroviral therapy
JPH08502044A (ja) ヒトウイルス感染の治療
Fritsch et al. Anti-retroviral therapy in HIV-1-infected persons: Concepts and strategies
Leonard Perspectives in HIV protease inhibitors
WO2018142288A1 (en) Mukaadial acetate isolated from warburgia salutaris and the use thereof as an antimalarial
Goodenow et al. Protease Inhibitors and HIV-1 Genetic Variability in Infected Children
MXPA01009885A (en) Viral treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100723

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101001

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101022

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110927